Development of a 99Tcm-labelled radiopharmaceutical for cerebral blood flow imaging

A new radiopharmaceutical, 99Tcm-hexamethylpropyleneamine oxime (99Tcm-HM-PAO) has shown considerable promise for single photon emission tomographic (SPECT) imaging of the brain. In animal biodistribution studies this complex demonstrates good brain uptake with prolonged retention of activity in bra...

Full description

Saved in:
Bibliographic Details
Published inNuclear medicine communications Vol. 6; no. 9; p. 499
Main Authors Nowotnik, D P, Canning, L R, Cumming, S A, Harrison, R C, Higley, B, Nechvatal, G, Pickett, R D, Piper, I M, Bayne, V J, Forster, A M
Format Journal Article
LanguageEnglish
Published England 01.09.1985
Subjects
Animals
Autoradiography
Brain - diagnostic imaging
Cerebrovascular Circulation
Oximes
Rats
Stereoisomerism
Technetium
Technetium Tc 99m Exametazime
Tomography, Emission-Computed - methods
Online AccessGet more information

Cover

More Information
Summary:A new radiopharmaceutical, 99Tcm-hexamethylpropyleneamine oxime (99Tcm-HM-PAO) has shown considerable promise for single photon emission tomographic (SPECT) imaging of the brain. In animal biodistribution studies this complex demonstrates good brain uptake with prolonged retention of activity in brain. Further improvement of these properties, resulting in higher brain uptake with very slow washout and fixed regional distribution has been achieved following the isolation of the d,1-diastereoisomer of HM-PAO.
ISSN:0143-3636
DOI:10.1097/00006231-198509000-00002